Expert Guidance for Mantle Cell Lymphoma

CME

Expert Guidance and Clinical Resources to Improve the Care of Patients With Mantle Cell Lymphoma

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 12, 2025

Expiration: November 11, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 73-year-old man presents with lymphadenopathy and left upper quadrant pain. Lymph node biopsy shows MCL, Ki-67 60%, TP53 mutation–negative disease. Staging revealed diffuse enlarged lymph nodes, bone marrow, and enlarged spleen (stage IVa). 

In your current practice, which of the following would you recommend as the optimal first-line treatment for this 73-year-old man?

2.

Which transplant-eligible patient with MCL would be the most appropriate candidate for the BOVen regimen (zanubrutinib/obinutuzumab/venetoclax) as first-line therapy?

3.

A 67-year-old man was diagnosed with MCL at age 62 but had no significant comorbidities. As frontline therapy, he received BR for 6 cycles followed by rituximab maintenance for 2 years. He experienced relapse at age 63 with diffuse lymphadenopathy. At that time, he was treated with ibrutinib (560 mg) for 2 years. Now, he has a diffuse relapse with pancytopenia, and bone marrow–positive disease with extensive lymphadenopathy.

In your current practice, what would you recommend as the optimal next-line treatment for this 67-year-old patient?

4.

What were the key results of the phase III ECHO trial testing acalabrutinib plus BR vs placebo plus BR for patients with previously untreated MCL?